In patients with critical findings identified on neuroimaging, most common comorbidities were hypertension, diabetes<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 24, 2020 (HealthDay News) — More than one-fifth of patients with COVID-19 presenting with neurologic findings who underwent neuroimaging had critical findings, according to a study scheduled for presentation at the annual meeting of the Radiological Society of North America, held virtually from Nov. 29 to Dec. 5.<\/p>\n
Colbey W. Freeman, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined use of neuroimaging in patients with COVID-19 presenting with neurologic complications. Overall, 1,357 severe acute respiratory syndrome coronavirus 2-positive patients were admitted; 81 (6 percent) underwent neuroimaging.<\/strong><\/p>\n The researchers found that 18 of the patients (22.2 percent) had critical findings on imaging (nine women\/nine men; 12 Black\/six White). Seven of the 18 were intubated and three were on veno-venous extracorporeal membrane oxygenation at some point. The most common comorbidities were hypertension and type 2 diabetes (13 and nine patients [72.2 and 50 percent], respectively). Three, three, 12, one, and four patients had subarachnoid and intraparenchymal hemorrhage, acute\/subacute infarct, hypoxic-ischemic encephalopathy, and large-vessel intracranial occlusion. Mean hemoglobin was below normal, while serum creatinine, D-dimer, and fibrinogen were elevated. Three of the patients died (16.7 percent).<\/p>\n “COVID-19 is associated with neurologic manifestations, and hypertension and type 2 diabetes mellitus are common in individuals who develop these manifestations,” Freeman said in a statement. “These populations may be at higher risk for neurologic complications and should be monitored closely.”<\/p>\n Press Release<\/a><\/p>\n